A Phase 1b, Open Label, Multicenter, Dose Escalation Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Trial Profile

A Phase 1b, Open Label, Multicenter, Dose Escalation Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs ABBV 838 (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Venetoclax (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors AbbVie
  • Most Recent Events

    • 13 Apr 2017 Planned End Date changed from 1 Aug 2020 to 1 Jan 2021.
    • 15 Feb 2017 Planned End Date changed from 1 Jan 2021 to 1 Aug 2020.
    • 15 Feb 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top